+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

UK Graves' disease Market 2019-2025

  • ID: 5116618
  • Report
  • February 2020
  • Region: United Kingdom
  • Orion Market Research Private Limited

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Allergan PLC
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
UK Graves’ disease Market Size, Share & Trends Analysis Report by Diagnosis (Ultrasound, Imaging Tests, Radioactive Iodine Uptake, and Blood Sample), by Treatment (Anti- Thyroid Medication, Radioactive Iodine Therapy, and Surgery) Forecast Period 2019-2025.

UK Graves’ disease market is growing at a CAGR of around 4.1% during the forecast period. Grave’s disease is one of the most prevalent autoimmune diseases across the UK. It is one of the leading causes of hyperthyroidism in the country. The disease is caused by a number of factors including the sedentary lifestyles, changing eating pattern, the prevalence of diabetes in the country are few of the key reasons which are expected to promote the demand of treatment and diagnostic services, which in turn increases the UK Graves’ disease market. The prevalence of diabetes has increased significantly in the UK. According to The British Diabetic Association 2017, nearly 3.7 million people were diagnosed with diabetes. Amongst this 10 %, people have type-1 diabetes. As the prevalence of such disease increases in the country, the risk associated with Grave’s disease is also increasing, thereby creating opportunities for the growth of the UK Graves’ disease market during the forecast period.

Further, the prevalence of Grave’s’ disease is majorly amongst the age group of 19-54. According to Eurostat, the working-age population in the UK accounted for 64.4% of the overall population. The prevalence of Grave’s disease also increases with changes in unhealthy eating patterns and smoking practices. It is observed that smoking is one of the key reasons which promote the prevalence of Grave’s disease in the working-age population. The percentage of population smoking in the UK is majorly between the age group of 25-34. Owing to this, the prevalence of Grave’s disease is expected to increase, thereby creating opportunities for the growth of the UK Graves’ disease market.

In addition, government initiative including the European Thyroid Association that has laid down numerous guidelines for the treatment of Grave’s hyperthyroid is also augmenting the market growth. As technology advances, the adoption of the surgical process for the treatment of Grave’s disease is expected to increase significantly in the coming years. Owing to this the proportion of patients treated from thyroidectomy is more from the Grave’s disease. This is expected to promote the growth of the UK Graves’ disease market in the near future.

Research Methodology:

The market study of the UK Graves’ disease market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. UK Graves’ Disease Market Research and Analysis by Diagnosis
2. UK Graves’ Disease Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive Research Methodology of the UK Graves’ disease market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK Graves’ disease market.
  • Insights about market determinants which are stimulating the UK Graves’ disease market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Allergan PLC
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown